S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:SERA

Sera Prognostics Stock Forecast, Price & News

$10.41
-0.59 (-5.36%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.31
$11.05
50-Day Range
$7.90
$11.41
52-Week Range
$7.61
$15.50
Volume
20,484 shs
Average Volume
71,525 shs
Market Capitalization
$304.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive SERA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.


Sera Prognostics logo

About Sera Prognostics

Sera Prognostics Inc. is a women's health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY.

Headlines

Oppenheimer Initiates Coverage on Sera Prognostics (NASDAQ:SERA)
November 18, 2021 |  americanbankingnews.com
Sera Prognostics (NASDAQ:SERA) Announces Earnings Results
November 10, 2021 |  americanbankingnews.com
Contrasting Sera Prognostics (NASDAQ:SERA) & DermTech (NASDAQ:DMTK)
November 7, 2021 |  americanbankingnews.com
Sera Prognostics Inc
October 19, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SERA
Phone
N/A
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$5.12 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$304.95 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/08/2022

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

927th out of 1,392 stocks

Medical Laboratories Industry

23rd out of 30 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Sera Prognostics (NASDAQ:SERA) Frequently Asked Questions

Is Sera Prognostics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sera Prognostics stock.
View analyst ratings for Sera Prognostics
or view top-rated stocks.

Are investors shorting Sera Prognostics?

Sera Prognostics saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 162,000 shares, an increase of 38.5% from the October 14th total of 117,000 shares. Based on an average daily volume of 67,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.8% of the shares of the stock are sold short.
View Sera Prognostics' Short Interest
.

When is Sera Prognostics' next earnings date?

Sera Prognostics is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Sera Prognostics
.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics Inc (NASDAQ:SERA) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.17. The firm earned $0.02 million during the quarter, compared to analyst estimates of $0.08 million.
View Sera Prognostics' earnings history
.

What price target have analysts set for SERA?

4 equities research analysts have issued 12 month price targets for Sera Prognostics' stock. Their forecasts range from $18.00 to $19.00. On average, they anticipate Sera Prognostics' stock price to reach $18.50 in the next year. This suggests a possible upside of 77.7% from the stock's current price.
View analysts' price targets for Sera Prognostics
or view top-rated stocks among Wall Street analysts.

When did Sera Prognostics IPO?

(SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

What is Sera Prognostics' stock symbol?

Sera Prognostics trades on the NASDAQ under the ticker symbol "SERA."

When does the company's lock-up period expire?

Sera Prognostics' lock-up period expires on Tuesday, January 11th. Sera Prognostics had issued 4,687,500 shares in its IPO on July 15th. The total size of the offering was $75,000,000 based on an initial share price of $16.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional investors include Interwest Venture Management Co. (8.25%), Bill & Melinda Gates Foundation (2.66%), Millennium Management LLC (0.55%), BlackRock Inc. (0.51%), Tudor Investment Corp Et Al (0.22%) and Citadel Advisors LLC (0.19%).

Which major investors are buying Sera Prognostics stock?

SERA stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Bill & Melinda Gates Foundation, Millennium Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, Citadel Advisors LLC, Geode Capital Management LLC, and Squarepoint Ops LLC.

How do I buy shares of Sera Prognostics?

Shares of SERA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sera Prognostics' stock price today?

One share of SERA stock can currently be purchased for approximately $10.41.

How much money does Sera Prognostics make?

Sera Prognostics has a market capitalization of $304.95 million.

How many employees does Sera Prognostics have?

Sera Prognostics employs 2,021 workers across the globe.

What is Sera Prognostics' official website?

The official website for Sera Prognostics is www.seraprognostics.com.

How can I contact Sera Prognostics?

The company can be reached via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.